PainReform

Pain Treatment Drugs

Health Tech & Life Sciences
Public on NASDAQ on Sep, 2020

Company Overview

Snapshot

Founded in December 2007, PainReform operates with 1–10 employees and has raised a total of $46.3 million across 5 funding rounds from 4 investors. The company went public on NASDAQ in September 2020.

Business overview

PainReform is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics. The company's core technology involves a proprietary drug-delivery system designed to provide extended post-surgical pain relief, aiming to reduce the reliance on opiates. PainReform leverages the 505(b)(2) regulatory pathway for FDA approval, which allows for new drug applications based on existing data, thereby streamlining clinical development. Its primary product, PRF-110, is based on the local anesthetic ropivacaine and targets the post-operative pain relief market within the Health Tech & Life Sciences sector, serving patients and providers.

Strategic signal

PainReform is strategically expanding its focus beyond pain management by advancing its DeepSolar Predict™ AI platform towards commercial launch, targeting revenue optimization in renewable energy markets. This move, highlighted in May 2026, signals a significant diversification strategy into AI-driven analytics, potentially opening new growth avenues and investor interest beyond its traditional pharmaceutical pipeline.

Company Intelligence Q&A

What was a significant recent development for PainReform's DeepSolar platform?
In May 2026, PRF Technologies, PainReform's DeepSolar division, advanced its DeepSolar Predict™ platform towards commercial launch. This AI platform is designed to optimize revenue across renewable energy markets, indicating a strategic expansion beyond the company's traditional pharmaceutical focus.
What was the outcome of the preclinical study for PRF-110 in May 2026?
In May 2026, PRF Technologies announced that PRF-110 demonstrated sustained 72-hour analgesic activity comparable to an approved, commercially available benchmark in a head-to-head preclinical study. This indicates positive progress in the development of its post-operative pain relief drug.
What strategic acquisition did PainReform complete in March 2025?
In March 2025, PainReform completed the strategic acquisition of DeepSolar. This acquisition is intended to unlock new growth opportunities in AI-driven solar analytics, marking a significant diversification for the company.
What was a key business update provided by PainReform in October 2025?
In October 2025, PainReform provided a business update for the six months ended June 30, 2025. This update included information on its DeepSolar division, which is developing "DeepSolar Predict" within the NVIDIA Connect Program and announced progress toward pilot projects.
When did PainReform go public on NASDAQ?
PainReform went public on NASDAQ in September 2020, raising $23 million in its Initial Public Offering.

External links